Sheldon Sloan's most recent trade in Spyre Therapeutics Inc. was a trade of 8,334 Common Stock done at an average price of $27.5 . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.46 per share. | 01 Jul 2026 | 8,334 | 8,334 (0%) | 0% | 27.5 | 228,852 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 8,334 | 305,000 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 87.52 per share. | 01 Jul 2026 | 6,500 | 1,834 (0%) | 0% | 87.5 | 568,880 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 88.34 per share. | 01 Jul 2026 | 1,834 | 0 (0%) | 0% | 88.3 | 162,016 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.46 per share. | 03 Jun 2026 | 8,333 | 8,333 (0%) | 0% | 27.5 | 228,824 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2026 | 8,333 | 313,334 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 03 Jun 2026 | 8,333 | 0 (0%) | 0% | 75 | 624,975 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.46 per share. | 01 May 2026 | 78,333 | 78,333 (0%) | 0% | 27.5 | 2,151,024 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2026 | 78,333 | 321,667 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 69.53 per share. | 01 May 2026 | 21,306 | 57,027 (0%) | 0% | 69.5 | 1,481,406 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.61 per share. | 01 May 2026 | 19,656 | 37,371 (0%) | 0% | 70.6 | 1,387,910 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 72.94 per share. | 01 May 2026 | 12,777 | 15,817 (0%) | 0% | 72.9 | 931,954 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 73.74 per share. | 01 May 2026 | 10,358 | 5,459 (0%) | 0% | 73.7 | 763,799 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.56 per share. | 01 May 2026 | 8,777 | 28,594 (0%) | 0% | 71.6 | 628,082 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 74.60 per share. | 01 May 2026 | 5,059 | 400 (0%) | 0% | 74.6 | 377,401 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 75.37 per share. | 01 May 2026 | 400 | 0 (0%) | 0% | 75.4 | 30,148 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 7,958 | 87,542 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 01 Apr 2026 | 7,958 | 0 (0%) | 0% | 50 | 397,900 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.66 per share. | 01 Apr 2026 | 7,958 | 7,958 (0%) | 0% | 21.7 | 172,370 | Common Stock |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 95,500 | 95,500 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Sheldon Sloan | Chief Medical Officer | 01 Oct 2024 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) |